RGRenate Grohmann

Renate Grohmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Renate Grohmann has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics

    by Nicole Moschny, Gudrun Hefner, Renate Grohmann, Gabriel Eckermann, Hannah B Maier, Johanna Seifert, Johannes Heck, Flverly Francis, Stefan Bleich, Sermin Toto, et al.

    Both inflammation and smoking can influence a drug’s pharmacokinetic properties, i.e., its liberation, absorption, distribution, metabolism, and elimination. Depending on, e.g., pharmacogenetics, these changes may alter treatment response or cause serious adverse drug reactions and are thus of clinical relevance. Antipsychotic drugs, used in the treatment of psychosis and schizophrenia, should be closely monitored due to multiple factors (e.g., the narrow therapeutic window of certain psychotropic drugs, the chronicity of most mental illnesses, and the common occurrence of polypharmacotherapy in psychiatry). Therapeutic drug monitoring (TDM) aids with drug titration by enabling the quantification of patients’ drug levels. Recommendations on the use of TDM during treatment with psychotropic drugs are presented in the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology; however, data on antipsychotic drug levels during inflammation or after changes in smoking behavior—both clinically relevant in psychiatry—that can aid clinical decision making are sparse. The following narrative review provides an overview of relevant literature regarding TDM in psychiatry, particularly in the context of second- and third-generation antipsychotic drugs, inflammation, and smoking behavior. It aims to spread awareness regarding TDM (most pronouncedly of clozapine and olanzapine) as a tool to optimize drug safety and provide patient-tailored treatment.


  • Acute urinary retention after treatment with doxepin and duloxetine

    by I Adamovic, R Grohmann, E Rüther, D Degner

    Tricyclic antidepressants (TCAs) are associated with well-known risks like anticholinergic side effects, orthostatic hypotension, weight gain as well as sedation. This case report presents a 70-year old man with a severe depression and prostata hyperplasia. This adverse drug reaction (urinary retention) was documented and analyzed by the pharmacovigilance program in German speaking countries „Arzneimittelsicherheit in der Psychiatrie“ (AMSP). At admission the patient got doxepin (CYP 2C19, 2D6, 1A2) 350 mg/d, plasma level (HPLC) doxepin+nordoxepin 436 µg/l (therapeutic range 50 – 150 µg/l). We reduced doxepin to 50 mg during a switch to duloxetine 60 mg (CYP 1A2, 2D6 inhibitor). Consequently, the patient developed an acute urinary retention. At this time, the plasma-level was 122 µg/l (doxepin+nordoxepin, no stay state). This case demonstrates the need to consider central anticholinergic effects of TCAs and other complex reasons for the development of an urinary retention. TDM showed high serum concentration of doxepin at the admission of the patient, but there were no adverse drug reaction. The combined treatment with duloxetine was associated with an acute urinary retention (pharmacodynamic and pharmacokinetic effects). A risk factor probably was the known prostata hyperplasia.


  • Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study

    by R. Grohmann, R. R. Engel, H.-J. Möller, E. Rüther, J. W. van der Velden, S. Stübner

    This study compares the first-generation antipsychotic (FGA) flupentixol to haloperidol and common second-generation antipsychotics (SGAs) as to drug utilization and severe adverse drug reactions (ADRs) in clinical treatment of schizophrenia inpatients using data from the drug safety program Arzneimittelsicherheit in der Psychiatrie (AMSP). AMSP drug utilization and reported ADR data were analyzed. Type and frequency of severe ADRs attributed to flupentixol were compared with haloperidol, clozapine, olanzapine, quetiapine, risperidone and amisulpride in a total of 56,861 schizophrenia inpatients exposed to these drugs. In spite of increasing prescription of SGAs, flupentixol was consistently used in schizophrenic inpatients (about 5 %) over time. Reporting rates of severe ADR ranged from 0.38 to 1.20 % for the individual antipsychotics (drugs imputed alone); flupentixol ranked lowest. The type of ADR differed considerably; as to severe EPMS, flupentixol (0.27 %), such as risperidone (0.28 %), held an intermediate position between haloperidol/amisulpride (0.55/0.52 %) and olanzapine/quetiapine (<0.1 %). The study is a heuristic approach, not a confirmatory test. Flupentixol has a stable place in the treatment of schizophrenia in spite of the introduction of different SGAs. Comparative ADR profiles suggest an intermediate position between FGAs and SGAs for flupentixol in clinical practice.


  • Open Access

    Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP

    by Anne Haeberle, Waldemar Greil, Stefan Russmann, Renate Grohmann

    Background: For the pharmacological treatment of bipolar depression several guidelines exist. It is largely unknown, to what extent the prescriptions in daily clinical routine correspond to these evidence based recommendations and which combinations of psychotropic drugs are frequently used. Methods: The prescriptions of psychotropic drugs were investigated of all in-patients with bipolar depression (n = 2246; time period 1994–2009) from hospitals participating in the drug surveillance program AMSP. For the drug use in 2010, 221 cases were analysed additionally. Results: From 1994 to 2009, 85% of all patients received more than one class of psychotropic substances: 74% received antidepressants in combination therapy, 55% antipsychotics, 48% anticonvulsants and 33% lithium. When given in combination, lithium is the most often prescribed substance for bipolar depression (33%), followed by valproic acid (23%), mirtazapine and venlafaxine (16% each), quetiapine (15%), lamotrigine (14%) and olanzapine (13%). Both, lithium and valproic acid are often combined with selective serotonin reuptake inhibitors (SSRI), but also with mirtazapine und venlafaxine. Combinations of more than one antidepressant occur quite often, whereby combinations with bupropion, paroxetine, fluoxetine or fluvoxamine are very rare. In 2010, quetiapine (alone and combined) was the most frequently prescribed drug (39%); aripiprazole was administered in 10%. Conclusion: Combinations of antidepressants (SSRI, mirtazapine, venlafaxine) with mood stabilizers (lithium, valproic acid, lamotrigine) and / or atypical antipsychotics (quetiapine, olanzapine) are common. Of most of those combinations the efficacy has not been studied. The use of aripiprazole and the concomitant use of two or three antidepressants contrast the guidelines.


  • Polypharmacy in psychiatric inpatients: Data from amsp (arzneimittelsicherheit in der psychiatrie), a european pharmacovigilance system

    by A. Konstantinidis, M. Letmaier, R. Grohmann, P. Stephan, R. Engel, S. Kasper

    IntroductionPsychotropic polypharmacy is widely used in routine clinical practice although there is still a substantial deficit in established knowledge about combination and augmentation treatments. Polypharmacy is related with a higher risk of adverse drug reactions and incompliance.MethodsOn two reference days per hospital and per year, the following data are recorded for all patients on the wards under AMSP surveillance: all drugs applied on that day with the daily dosage for psychotropic drugs, ICD diagnosis, age, and sex. Data is stored at the study center in Munich. We evaluated data from 2000 (N = 5669) and 2007 (N = 8346).ResultsFrom 2000 to 2007 inpatient prescriptions including three or more drugs increased significantly from 59.4% to 69.3% (chi2: 144.913; df:1; p < 0.001). Furthermore the percentage of inpatients being prescribed three or more psychotropics increased significantly from 36.5% in 2000 to 47.97% in 2007 (chi2: 180.01; df:1; p < 0.001).Investigating further, which inpatients, diagnosed according to ICD-10, tend to be treated with more than two psychotropics, we found that this was more common in inpatients, who had an F2., F3. or F9. ICD-10 diagnosis. Especially inpatients with a bipolar disorder (F31.) showed an extremely high rate for psychotropic polypharmacy with three or more psychotropic drugs, with rates of 63,8% in 2000 and 75,2% in 2007.ConclusionPolypharmacy is still gaining ground. Our results show that psychotropic agents are commonly used in combination; therefore further studies evaluating assumable positive results of psychotropic combinations are needed.


  • Polypharmacy in a Psychiatric Inpatient Population: Results from the AMSP (Arzneimittelsicherheit in der Psychiatrie) Study Group

    by A. Konstantinidis, U. Moser, R. Grohmann, A. Horvath, R. Engel, S. Kasper

  • Drug safety monitoring in psychiatry: drug induced seizures in antidepressant treatment

    by I. Adamovic, R. Grohmann, S. Kropp, E. Rüther, D. Degner

    Aim of the presented study was to investigate epileptic seizures in AD treatment under natural conditions. The AMSP (Arzneimittelsicherheit in der Psychiatrie) project is a drug safety program for the assessment of adverse drug reactions (ADR) of psychotropic drugs (1). Data collection started in 1993, in 2003 40 psychiatric hospitals in Germany, Austria and Switzerland participate. 78.155 patients treated with AD were monitored (32.311 patients under tricyclic antidepressants (TCA), 27.454 under serotonin reuptake inhibitors (SSRI)). Totally 58 cases of Grand mal seizure were recorded (0,07%). The incidence rates were highest for TCA with 0,04%, followed by SSRI (0,02%). Within the TCA class the incidence rates were: maprotiline 0,03%, doxepin/clomipramine 0,02%. Within the SSRI class paroxetine (0,02%), sertralin (0,01%) were the most relevant associated with seizure. We recorded incidence rates of 0,008% in mirtazapine/venlafaxine. In about half of all drug-induced seizures, combination treatments with other psychotropic drugs were imputed. There was a strong difference between the AD groups. Combination treatment seems to be the most relevant risk factors for seizures (pharmacodynamic and -kinetic interactions). The systematic assessment of ADR due to AD by the AMSP project can yield data for establishing risk profiles of single drugs.

  • „Atypical Dyskinesia“ – Uncommon Adverse Reactions due to Psychotropic Drugs

    by S. Stübner, R. Grohmann, R. Engel, H. J. Möller, H. Hippius, E. Rüther

    Disorders of involuntary movement due to psychotropic drugs (1) pose a major problem when treating mentally ill patients. The drug safety program in psychiatry AMSP (Arzneimittelsicherheit in der Psychiatrie) documents uncommon or severe adverse drug reactions (ADR). The epidemiological data for the surveyed population are systematically analyzed as regards the patient's history of medication, comedication, and clinical course. Between 1993 and 2003, 31 episodes were documented as „atypical dyskinesia“, i.e. ADRs, which were uncommon in duration between the onset of treatment and the start of ADR or clinical symptomatology. We differentiated between atypical dyskinesias, which showed an unusual time of onset – resembled acute dystonia, but had a late onset; or conversely: they were similar to tardive dyskinesia, but showed an early onset and those, which were completely uncommon. It is not possible to provide a valid explication of these strange EPMS-like phenomena. Remarkably, atypical neuroleptics seemed to be overrepresented (involved in 20 of 31 cases). Details of these cases shall be presented. At the present time, only the clinical observations can be documented and drawn attention to. It is apparently important to be attentive to ADRs that are new, uncommon, or not yet classified. References: 1) Stübner et al. Pharmacopsychiatry 2004.

  • AMSP Methods and Results on Severe ADR due to Antipsychotics

    by R. Grohmann, S. Bender, R. Engel, E. Rüther

    The AMSP (Arzneimittelsicherheit in der Psychiatry) study is a drug safety program that ensures the continuous assessment of severe adverse drug reactions (ADR) in psychiatric inpatients under the natural conditions of routine clinical treatment. Currently 45 hospitals participate in the study. The methods of the AMSP are described, including detailed definitions of ADRs assessed to be „severe“, and the implications of these definitions and the methodological approach for evaluating the AMSP data are discussed. Until the end of 2000, 86,439 patients treated with at least one neuroleptic agent were monitored. In 1.1% of the patients severe ADR occurred. In contrast to the results from controlled trials, ‘atypical’ neuroleptics caused more severe ADR than ‘typical’ neuroleptics. This result was mainly caused by the high amount of severe ADR in patients treated with clozapine. ‘Atypical’ neuroleptics were found to be superior in EPS and urological ADR. Excluding the data on clozapine, we found ‘typical’ and ‘atypical’ neuroleptics to be similar in the occurrence of severe ADR, although the profiles differ between these two groups as well as between the single substances. In addition, recent data on neuroleptics acquired in the AMSP program from 2001–2003 are analysed. The AMSP data provide valuable information on type and frequency of ADR in psychiatric practice thus enabling differential indication of neuroleptics not only based on the efficacy and tolerability data of controlled trials but also on their differential ADR profile occurring in the ‘real life’ setting of routine clinical treatment.